Following a PBM audit that uncovered a $6.5 million billing discrepancy, federal prosecutors opened an investigation. After HLA was retained, the U.S. Attorney's Office for the Eastern District of Pennsylvania agreed to a $2.5 million civil settlement in which the Owner denied all wrongdoing.

HLA is pleased to announce the declination of criminal charges against a Pennsylvania pharmacy and owner arising from a $6.5 million inventory shortfall. Following a PBM audit referral to federal prosecutors, the case was resolved civilly by HLA's client for a fraction of the claims paid.

PBM audit win

Federal Prosecutors Encourage PBM Referrals

The President is responsible for appointing a United States Attorney in each federal district and state. The U.S. Attorney serves as the top federal law enforcement official in each state, and reports to the Attorney General of the United States.

Competition exists among U.S. Attorney's Offices for the biggest and most noteworthy cases. In addition, year-after-year, the Department of Justice prioritizes healthcare enforcement given the amount of money involved.

Accordingly, federal prosecutors often cultivate relationships with private industry, including payors and PBMs, to receive investigative "leads." These leads are investigated by the FBI, HHS-OIG, and other federal agents and investigators.

Compounding is an Audit Risk Factor

Compounding is less prolific now, but federal and state agencies remain vigilant to this practice given their experience with compounding schemes and Tricare fraud in years past.

This case involved a PBM audit that noted discrepancies in compound pain creams, and referred the matter for investigation to the U.S. Attorney's Office for the Eastern District of Pennsylvania.

The Government's Investigation

Following a lengthy investigation, the U.S. Attorney's Office alleged that the Pharmacy, Owner, and business partners had billed Medicare approximately $6.5 million in compound creams even though the pharmacy's records indicated that it had never purchased the APIs in those creams.

In addition, the federal government alleged that Owner had violated laws relating to controlled substances, including Schedule II substances.

HLA's Defense Strategy

Because HLA's founding partner previously served for nearly a decade as an Assistant U.S. Attorney, we understand the risks involved when dealing with the Department of Justice. In this case, we sought to persuade the government that operational errors, not criminal intent, had been the cause of the discrepancy.

Ultimately, the U.S. Attorney's Office agreed with HLA. As a result, Owner was not criminally charged.

Civil Settlement & Resolution

Instead, the U.S. Attorney's Office agreed to resolve the case based on a civil settlement of $2.5 million, a small fraction of the $6.5 million discrepancy at issue. In addition, Owner admitted no wrongdoing, was not excluded, and did not suffer licensing sanctions or professional discipline.

Finally, the settlement resolved all alleged violations of the Controlled Substances Act with no collateral consequences for the Owner.

HLA is Available to Help

If you are facing an aggressive PBM audit with inventory or other discrepancies, call or email before the audit gets referred to law enforcement. If you are the subject of an investigation by law enforcement, we can help stop charges being brought. And if you are the subject of filed criminal charges, we can help resolve the matter before trial or defend your innocence in court.

Frequently Asked Questions

HLA Files Emergency Texas Lawsuit Against Optum PBM Audit Termination

Health Law Alliance announces the filing of an emergency lawsuit in federal court for the Northern District of Texas, Dallas Division, to stop Optum's termination of an independent pharmacy that dispensed medications on telemedicine prescriptions and force Optum to comply with federal and state "prompt payment" laws that prohibit withholding of reimbursement.

Read More >>

Pharmacy Benefit Managers (PBMs) Face Possible FTC Lawsuit

The Federal Trade Commission (FTC) plans to sue the top Pharmacy Benefit Managers (PBMs) for anti-competitive practices, including influencing drug prices and favoring their own networks, which disadvantage independent pharmacies and raise prescription drug costs.

Read More >>

Victories Against Optum Rx: Protecting Pharmacy Clients Nationwide

Health Law Alliance has successfully challenged Optum Rx's termination decisions for numerous pharmacies, ensuring they can continue to operate and serve their communities. These victories highlight the firm's expertise in healthcare law and its dedication to protecting pharmacy clients from unjust PBM actions.

Read More >>

FTC Issues Interim Report Condemning Anticompetitive PBM Practices

The top Pharmacy Benefit Managers (PBMs) are condemned by the FTC for manipulating the healthcare system to generate significant profits, thereby inflating drug costs and overcharging patients, particularly for critical medications like cancer drugs.

Read More >>